综合性癌症中心
美国顶尖的癌症中心之一
The UCLA Health 约翰逊综合癌症中心 (UCLA Health JCCC) attained designation as a "comprehensive cancer center" by the National Cancer Institute (NCI) in 1976, 证明了它在癌症研究方面的持续卓越, 教育, 并延伸到洛杉矶县皇冠hga020电脑版和更远的地方. 与皇冠hga025大学洛杉矶分校健康中心建立了强有力的合作伙伴关系，为癌症患者提供卓越的护理, 预防, 和生存.
皇冠hga025大学洛杉矶分校健康中心, teams of specialists work together to treat and assist cancer patients and their families. A multidisciplinary approach helps patients and family members confront both the immediate and long-term effects of cancer. 作为nci指定的综合性癌症中心, 皇冠hga025大学洛杉矶分校健康JCCC致力于减少或消除癌症负担方面的差异, to ensure that all share equally in the medical advances that result from cancer research.
最先进的癌症治疗方法
The UCLA Health JCCC has an international reputation for developing new cancer therapies, 提供最好的实验和传统治疗方法. Center members conduct research on a wide range of cancers and the Center offers patients the opportunity to participate in clinical trials and research. The UCLA Health JCCC has over 500 active cancer clinical trials at any given time that are enrolling patients, and offers many of these trials not only to residents of Los Angeles County but at partner institutions and affiliate sites across the country.
发现癌症防治的新突破
有500多名医生和科学家, the UCLA Health JCCC is one of the largest comprehensive cancer centers in the nation. With an international reputation for providing the best in experimental and traditional cancer treatments, UCLA Health JCCC experts also train and educate the next generation of medical researchers. 成功的靶向癌症治疗，如曲妥珠单抗, 伊马替尼, enzalutamide, and others were 发达 from basic studies performed in Center laboratories and brought to clinical trials for UCLA cancer patients.
全国癌症综合网络
The UCLA Health JCCC is also one of 33 leading cancer centers in the United States participating in the 全国癌症综合网络 (NCCN). 作为NCCN成员, UCLA Health JCCC experts join experts from other Centers in setting the standards for 诊断 and treating patients with cancer, 特别关注不寻常, 复杂的, 或者是侵袭性的疾病.
历史 & 任务
在60年代末, 一群科学家, 临床医生, and volunteers at UCLA came together to develop a cancer center that would become renowned for excellence in research, 教育, 病人护理. 今天, the UCLA Health 约翰逊综合癌症中心 (UCLA Health JCCC) is a global leader in cancer research, 教育, 临床护理的使命是加速发现预防和治疗癌症.
皇冠hga025大学洛杉矶分校健康JCCC是其中之一 只有57个国家癌症研究所(NCI)指定的综合癌症中心 in the nation, attaining the founders’ aspiration with the highest designation possible from the NCI. The NCI recognizes comprehensive cancer centers from around the country that meet rigorous standards for transdisciplinary, state-of-the-art research focused on developing new and better approaches to preventing, 诊断, 为这些中心所服务的皇冠hga020电脑版治疗癌症. 皇冠hga025大学洛杉矶分校健康JCCC举办了这个活动
为什么选择我们的癌症中心?
该领域的领导者
我们有超过 500名科学家和医生 who conduct basic and translational cancer research and provide comprehensive cancer care
改变治疗
自2014年以来, research at the UCLA Health 约翰逊综合癌症中心 has led or contributed to 22日批准 从FDA获得新的癌症治疗或方案，这是一个了不起的成就.
数十年的经验
The UCLA Health 约翰逊综合癌症中心 has held the highest designation possible from the National Cancer Institute (NCI) since 1976.
Dr. 丹尼斯Slamon discovered the relationship between the HER-2/neu gene and an aggressive form of breast cancer found in about 30 percent of patients. 这一发现导致了新型乳腺癌药物的开发 赫赛汀, FDA于9月25日批准, 1998, 使其成为首个被批准的从基因根源攻击癌症的治疗方法.
开发的 Dr. 安东尼里巴斯, Keytruda 9月14日FDA批准了首个免疫疗法吗, 2014年治疗晚期黑色素瘤. 这标志着致命皮肤癌治疗方式的范式转变, the research was conducted at UCLA and 11 other sites across the world as part of the largest phase 1 clinical study in the history of oncology.
根据里巴斯的研究， Dr. 爱德华Garon 领导了迄今为止发表的使用免疫疗法治疗肺癌的最大研究. 它于10月2日获得了FDA的批准, 2015年，Keytruda用于晚期非小细胞肺癌. 2014年10月，FDA授予该药“突破性疗法”地位, 允许它快速获得批准.
In 2014, 加隆也是一项多年研究的首席研究员, 的国际三期临床试验 Cyramza. 测试在1个以上,200名患者, the drug was found to extend survival significantly in NSCLC and approved by the FDA on December 12, 2014.
Slamon和 Dr. 理查德·芬恩 发达 IBRANCE, a groundbreaking new treatment strategy to arrest tumor growth in women with estrogen-receptor positive advanced breast cancer. 2015年2月3日获FDA批准.
转化研究进展
肉瘤
Dr. 弗雷德Eilber 开发了一种残肢抢救技术，现已成为全国样板. 他在手术前对肉瘤患者进行化疗, 避免了截肢，否则就需要截肢.
卵巢癌
Dr. Mark Pegram led the team of Jonsson 癌症中心 doctors who were the first to treat ovarian cancer patients with gene therapy using the p53 tumor suppressor gene.
肾癌
Drs. Robert Figlin and Arie Belldegrun 发达 a new approach to treating metastatic kidney cancer by combining biologic and cellular therapies to extend re任务 times.
病人恢复
Dr. Judith Gasson及其同事纯化了GM-CSF, which shortened the time it takes for cancer patients to recover their white blood cell counts (from five to two weeks) after bone marrow transplants.
BMT
Dr. 约翰-格兰斯潘说 博士和. Mary Territo used megakaryocyte growth and development factor (MGDF) for the first time to speed up a cancer patient´s bone marrow recovery after transplant.
饮食和营养
Glaspy demonstrated for the first time that dietary regulation of certain fatty acids can change the composition of human breast tissue in such a way that it may be more resistant to cancer.
乳腺癌
In 1992, UCLA Health opened the first multidisciplinary breast cancer center on the West Coast, the 露华浓/UCLA乳房中心对于有乳房问题或患乳腺癌风险高的女性来说，这是一项非常重要的建议.
前列腺癌
Dr. 查尔斯·索耶斯发明了第一个前列腺癌动物模型, and the ability to grow those cells in animals provided researchers with a crucial new research tool.
